A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma

Talpur, Rakhshandra; Chockalingam, Ramya; Wang, Casey; Tetzlaff, Michael T.; Duvic, Madeleine

doi:10.1016/j.clml.2015.11.013

Cited by 17 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 20% of tumor cells in our current case expressed CD30. Recently, the efficacy of brentuximab vedotin in CD30 + CGD-TCL cases was also reported, 11 suggesting that brentuximab vedotin can be a treatment option for patients with CD30 + CGD-TCL.…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous γδ T‐cell lymphoma with unusual immunophenotype: A case report and review of published work

Kamijo

Miyagaki

Norimatsu³

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Primary cutaneous γδ T‐cell lymphoma (CGD‐TCL) is a rare form of primary cutaneous lymphoma. The histopathological features of CGD‐TCL are still unclear because of its rarity. Here, we report a case of a 77‐year‐old Japanese man who presented with a 9‐month history of erythematous plaques on his left forearm. Skin biopsy specimens revealed the infiltration of atypical medium/large‐sized lymphocytes from the epidermis to the deep dermis. Atypical lymphocytes were positive for CD3, CD5, CD8 and Vδ1, and negative for CD4, CD7, CD56, EBER‐ISH, intracellular antigen‐1, granzyme B and perforin. CD30 was partially expressed. We also reviewed 246 cases of CGD‐TCL from the published work. CD4−CD8− double‐negative cases were 113 of 196 cases (57.6%), followed by CD4−CD8+ cases (52/196, 26.5%). CD5 was expressed in 25.8% of the cases (34/132). At least one cytotoxic molecule marker was expressed in 150 of 160 cases (93.8%). Some cases showed an indolent clinical course, especially in mycosis fungoides‐like CGD‐TCL cases. CD5 positivity and lack of cytotoxic molecule expression could be associated with a better prognosis. In addition, CD30 expression was found in approximately half of CGD‐TCL cases (51/112 cases), suggesting that brentuximab vedotin could be a good treatment option for such patients. Further studies with more cases with detailed clinical and pathological information are necessary to elucidate the etiology and prognostic markers of this entity.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary cutaneous γδ T‐cell lymphoma with unusual immunophenotype: A case report and review of published work

Kamijo

Miyagaki

Norimatsu³

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…This report suggested that brentuximab vendotin, which was previously Food and Drug Administration (FDA) approved for therapy of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and lymphomatoid papulosis, could be potentially expanded to PCGD-TCL. Although a sample size of only four patients, three patients had a positive response after four to six cycles of brentuximab vendotin and one patient had a minor response after two cycles [18]. This demonstrates the need for continued advancement for treatment regimens for PCGD-TCL.…”

Section: Discussionmentioning

confidence: 92%

Primary Cutaneous Gamma/Delta T-cell Lymphoma and Hemophagocytic Lymphohistiocytosis Associated With AIDS

Khadilkar

Adashek

Riddle

et al. 2020

Cureus

View full text Add to dashboard Cite

Primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL) is a rare lymphoma that makes up less than 1% of all cutaneous T-cell lymphomas. Patients with PCGD-TCL typically present with rapidly progressing plaques and ulceronecrotic nodules most frequently located on extremities without lymph node or bone marrow involvement. The overall prognosis is poor with a median overall survival of approximately 15 months. This case highlights a patient with concomitant PCGD-TCL, hemophagocytic lymphohistiocytosis, and human immunodeficiency virus-1-acquired immunodeficiency syndrome. There is a paucity of case reports describing PCGD-TCL and there are no evidence-based treatment recommendations. Further studies are needed to optimize strategies to treat patients with these diseases.

show abstract

“…The interest of the present case is related to the long‐lasting, complete remission after allogeneic transplantation, and the very good and rapid response on relapse to treatment with BV 4 . BV is an antibody–drug conjugate with a CD30‐directed antibody linked to monomethyl auristatin E (MMAE).…”

Section: Figurementioning

confidence: 99%

“…Following binding to CD30, BV is internalized by the targeted cells leading to release of MMAE, which in turn causes cell cycle arrest and cell death by inhibition of microtubule polymerization 5 . Four cases of primary cutaneous GD‐TCL have been published in a case series by Talpur and coworkers, 4 with one of their cases experiencing a CR after relapsing from an allogeneic bone marrow transplantation. Although rare, aberrant expression of CD30 in GD‐TCL cancer cells may be therapeutically exploited using BV.…”

Section: Figurementioning

confidence: 99%

Complete remission with brentuximab vedotin in a case of primary cutaneous gamma‐delta T‐cell lymphoma relapsed after allogeneic stem cell transplantation

et al. 2021

View full text Add to dashboard Cite

show abstract

A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma

Cited by 17 publications

References 7 publications

Primary cutaneous γδ T‐cell lymphoma with unusual immunophenotype: A case report and review of published work

Primary cutaneous γδ T‐cell lymphoma with unusual immunophenotype: A case report and review of published work

Primary Cutaneous Gamma/Delta T-cell Lymphoma and Hemophagocytic Lymphohistiocytosis Associated With AIDS

Complete remission with brentuximab vedotin in a case of primary cutaneous gamma‐delta T‐cell lymphoma relapsed after allogeneic stem cell transplantation

Contact Info

Product

Resources

About